Table 1.
Patient characteristics.
Table 2.
Quality controls of 89Zr-rituximab.
Fig 1.
Example of whole body distribution of 89Zr-rituximab over time.
Maximum intensity projections at D0, D3 and D6 p.i. for patient 3.
Fig 2.
Biopsies ranked in order of increasing CD20 expression.
Per panel the CD20 rank is indicated in the right upper corner and the patient number in the left lower corner. 1) Core-needle biopsy of DLBCL (liver) in patient 1 shows completely absent CD20 expression. 2) Core-needle biopsy of DLBCL (axillar lymph node) in patient 6 showing almost completely absent CD20 expression: extremely sparse groups of CD20-positive tumor cells with granular staining pattern, considered as absent CD20 expression. 3) Excision biopsy of DLBCL (cervical lymph node) in patient 2 shows heterogeneously positive CD20 expression in sparse groups of cells, granular staining pattern. 4) Excision biopsy of DLBCL (nasopharynx) in patient 5 showing heterogeneously positive CD20 expression in the majority of cells, membranous staining pattern. 5) Excision biopsy of DLBCL (retroperitoneal lymph node) in patient 4 showing uniformly positive CD20 expression, membranous staining pattern. 6) Excision biopsy of DLBCL (inguinal lymph node) in patient 3 showing uniformly positive CD20 expression, membranous staining pattern.
Fig 3.
No tumor uptake on 89Zr-rituximab-PET, concordant with CD20 expression in biopsy.
Axial images, from left to right attenuation corrected PET, low dose CT and fused PET/CT image of patient 1. a) 89Zr-rituximab-PET shows no tumor uptake concordant with a CD20-negative liver biopsy. b) Corresponding tumor location on 18F-FDG-PET.
Fig 4.
Example of tumor uptake on 89Zr-rituximab-PET, concordant with CD20 expression in biopsy.
Axial images, from left to right attenuation corrected PET, low dose CT and fused PET/CT image of patient 3. a) 89Zr-rituximab-PET shows intense tumor uptake concordant with a CD20-positive biopsy (inguinal lymph node). b) Corresponding tumor location on 18F-FDG-PET.
Fig 5.
Tumor uptake on 89Zr-rituximab-PET, discordant with CD20 expression in biopsy.
Axial images, from left to right attenuation corrected PET, low dose CT and fused PET/CT image of patient 6. a) 89Zr-rituximab-PET shows tumor uptake discordant with a CD20-negative biopsy (axillar lymph node). b) Corresponding tumor location on 18F-FDG-PET.
Table 3.
Quantitative tumor uptake measures of 89Zr-rituximab in the biopsied tumor lesions.